Prosecution Insights
Prosecution Insights
14 pending office actions • 13 art units • 14 examiners • 0 of 14 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (7%) |
| §101 + other | 1 (7%) |
| §103 only | 3 (21%) |
| §102 only | 1 (7%) |
| §112 only | 1 (7%) |
| Double-patenting + other | 3 (21%) |
| Multi-statute (no §101) | 4 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEY, GENEVIEVE S | 1 | 60.3% | +48.4% |
| FRASER, STEWART A | 1 | 86.0% | +14.3% |
| SCHUBERG, LAURA J | 1 | 23.7% | +37.2% |
| WELLES, COLMAN THOMAS | 1 | 25.0% | +49.0% |
| AVERY, BRIAN WILLIAM | 1 | 60.2% | +55.0% |
| RAYMONDA, MATTHEW HAROLD | 1 | 35.7% | +55.0% |
| CHANDRA, GYAN | 1 | 71.3% | +27.4% |
| DUFFY, PATRICIA ANN | 1 | 52.7% | +34.2% |
| DEBERRY, REGINA M | 1 | 50.0% | +30.4% |
| CONSTANTINE, CHARLES Z | 1 | 59.0% | +48.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17912480 | ISCHEMIC HEART DISEASE ANIMAL MODEL USING 3-DIMENSIONAL BIOPRINTED OCCLUDE, AND MANUFACTURING METHOD THEREFOR | WESTON, ALYSSA G | 9d |
| 17968902 | METHOD FOR ANALYZING GENETIC INTERACTION OF CANCER VIA MOLECULAR NETWORK REFINING PROCESS, AND SYSTEM USING SAME | SKIBINSKY, ANNA | 12d |
| 18375599 | COMPOSITION FOR ENHANCING GROWTH OF PLANTS | WELLES, COLMAN THOMAS | 21d |
| 18065810 | NOVEL MICROORGANISM FOR POLYSTYRENE BIODEGRADATION | LEE, JAE W | 22d |
| 18395922 | NOVEL ORGANOTIN SILICATE COMPOUNDS, PREPARATION METHODS THEREOF AND PHOTORESIST COMPOSITION CONTAINING THE SAME | FRASER, STEWART A | — |
| 18287435 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PARKINSON'S DISEASE, AND PREPARATION METHOD THEREOF | SCHUBERG, LAURA J | — |
| 18032909 | FLAGELLIN FUSION PROTEIN AND USE THEREOF | DUFFY, PATRICIA ANN | — |
| 17775101 | SYNTHETIC ALPHA-SECRETASE AND USE THEREOF | ARMATO JR, DENNIS IGNATIUS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18032902 | COMPOSITION FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE OR METABOLIC SYNDROME, COMPRISING FLAGELLIN FUSION PROTEINS | CHANDRA, GYAN | 44d overdue |
| 18317965 | SYSTEM AND METHOD FOR VERIFYING USER BY SECURITY TOKEN COMBINED WITH BIOMETRIC DATA PROCESSING TECHNIQUES | AVERY, BRIAN WILLIAM | 2d overdue |
| 18375599 | COMPOSITION FOR ENHANCING GROWTH OF PLANTS | WELLES, COLMAN THOMAS | 21d |
| 18696589 | PHARMACEUTICAL COMPOSITION FOR TREATING INFLAMMATORY DISEASES | ALLEY, GENEVIEVE S | — |
| 18395922 | NOVEL ORGANOTIN SILICATE COMPOUNDS, PREPARATION METHODS THEREOF AND PHOTORESIST COMPOSITION CONTAINING THE SAME | FRASER, STEWART A | — |
| 18287435 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PARKINSON'S DISEASE, AND PREPARATION METHOD THEREOF | SCHUBERG, LAURA J | — |
| 18251188 | COMPOSITION FOR TARGETING CANCER CELL, COMPRISING STRAIN EXPRESSING MONOMERIC STREPTAVIDIN, AND BIOTINYLATED COMPOUND | RAYMONDA, MATTHEW HAROLD | — |
| 18032909 | FLAGELLIN FUSION PROTEIN AND USE THEREOF | DUFFY, PATRICIA ANN | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1631 | 1 |
| 1612 | 1 |
| 2495 | 1 |
| 1653 | 1 |
| 1674 | 1 |
| 1645 | 1 |
| 1647 | 1 |
| 1657 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18696589 | PHARMACEUTICAL COMPOSITION FOR TREATING INFLAMMATORY DISEASES | ALLEY, GENEVIEVE S | 1617 | §103DP | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18395922 | NOVEL ORGANOTIN SILICATE COMPOUNDS, PREPARATION METHODS THEREOF AND PHOTORESIST COMPOSITION CONTAINING THE SAME | FRASER, STEWART A | — | §102§103 | Non-Final OA | — | Pending | Dec 26, 2023 |
| 18287435 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PARKINSON'S DISEASE, AND PREPARATION METHOD THEREOF | SCHUBERG, LAURA J | 1631 | §102 | Final Rejection | — | Pending | Oct 18, 2023 |
| 18375599 | COMPOSITION FOR ENHANCING GROWTH OF PLANTS | WELLES, COLMAN THOMAS | 1612 | §103 | Non-Final OA | 21d | Pending | Oct 02, 2023 |
| 18317965 | SYSTEM AND METHOD FOR VERIFYING USER BY SECURITY TOKEN COMBINED WITH BIOMETRIC DATA PROCESSING TECHNIQUES | AVERY, BRIAN WILLIAM | 2495 | §103 | Non-Final OA | 2d overdue | Pending | May 16, 2023 |
| 18251188 | COMPOSITION FOR TARGETING CANCER CELL, COMPRISING STRAIN EXPRESSING MONOMERIC STREPTAVIDIN, AND BIOTINYLATED COMPOUND | RAYMONDA, MATTHEW HAROLD | 1653 | §102§103§112DP | Non-Final OA | — | Pending | Apr 28, 2023 |
| 18032902 | COMPOSITION FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE OR METABOLIC SYNDROME, COMPRISING FLAGELLIN FUSION PROTEINS | CHANDRA, GYAN | 1674 | §112 | Non-Final OA | 44d overdue | Pending | Apr 20, 2023 |
| 18032909 | FLAGELLIN FUSION PROTEIN AND USE THEREOF | DUFFY, PATRICIA ANN | 1645 | §103§112 | Non-Final OA | — | Pending | Apr 20, 2023 |
| 18030584 | NOVEL PROTEIN SPECIFICALLY BINDING TO CALRETICULIN AND HAVING HUMAN FIBRONECTIN DOMAIN III SCAFFOLD AND USE THEREOF | DEBERRY, REGINA M | 1647 | §102§103DP | Non-Final OA | — | Pending | Apr 06, 2023 |
| 18002292 | SALMONELLA STRAIN FOR TREATING CANCER AND USE THEREOF | CONSTANTINE, CHARLES Z | 1657 | §103 | Final Rejection | — | Pending | Dec 19, 2022 |
| 18065810 | NOVEL MICROORGANISM FOR POLYSTYRENE BIODEGRADATION | LEE, JAE W | 1656 | §101 | Non-Final OA | 22d | Pending | Dec 14, 2022 |
| 17968902 | METHOD FOR ANALYZING GENETIC INTERACTION OF CANCER VIA MOLECULAR NETWORK REFINING PROCESS, AND SYSTEM USING SAME | SKIBINSKY, ANNA | 1635 | §101§112 | Final Rejection | 12d | Pending | Oct 19, 2022 |
| 17912480 | ISCHEMIC HEART DISEASE ANIMAL MODEL USING 3-DIMENSIONAL BIOPRINTED OCCLUDE, AND MANUFACTURING METHOD THEREFOR | WESTON, ALYSSA G | 1633 | §102§103 | Non-Final OA | 9d | Pending | Sep 16, 2022 |
| 17775101 | SYNTHETIC ALPHA-SECRETASE AND USE THEREOF | ARMATO JR, DENNIS IGNATIUS | 1651 | §103§112 | Final Rejection | — | Pending | May 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial